I-Buyback eZinzileyo evela kubaThengi CAS 782487-28-9 Rosiptor Umgangatho oLungileyo Ixabiso eliPhezulu eliThengisisiweyo eliTshayo loKhuseleko lweStokhwe ngenqanawa Ucoceko oluPhezulu 99%-ikopi

Imveliso yokuqala ye-semaglutide yaphuhliswa nguNovo Nordisk kwaye ibonakaliswe kubantu abadala abanesifo sikashukela sohlobo lwe-2. Igama lokurhweba lemveliso yokutofa yi-Ozempic®, enokusetyenziswa kanye ngeveki. Kuvunyiwe ukuthengiswa yi-US Food and Drug Administration (FDA) ngoDisemba 5, 2017, kunye ne-European Medicines Agency (EMA) ngoFebruwari 8, 2018. Yavunywa ukuthengiswa yi-Arhente ye-Japan Pharmaceuticals and Medical Devices Agency. PMDA) ngo-Matshi 23, 2018. Isicelo sokuthengisa sifakwe kwi-China Medical Products Administration (NMPA) ngo-Aprili 4, i-2020, kwaye ngoku iphantsi kovavanyo kunye nokuvunywa. Igama lebhrendi ye-chemicalbook yemveliso yethebhulethi yomlomo, i-Rybelsus®, yamkelwa yi-FDA nge-20 kaSeptemba 2019, i-EMA yaseYurophu ngoMatshi ka-2020, kunye ne-PMDA yaseJapan ngoJuni ka-2020. Lichiza lokuqala lomlomo le-GLP- 1 kwihlabathi. I-Semaglutide (i-0.5 mg okanye i-1 mg injection) ingasetyenziselwa ukunyanga uhlobo lwe-2 yeswekile kubantu abadala. Eli chiza liyi-glucagon-like peptide (GLP-1) i-receptor agonist, evuselela ukukhutshwa kwe-insulin kunye nokunciphisa ukukhutshwa kweglucagon. Ubomi besiqingatha sokubophelela kwi-albumin yegazi yiveki ye-1, ngoko kufuneka ilawulwe kanye ngeveki ngepeni efakwe ngaphambili. Uncedisa ukutya kunye nokuzivocavoca ukuphucula ulawulo lweswekile yegazi kubantu abadala abanesifo sikashukela sohlobo lwe-2.